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Summary
Activating mutations in the ras oncogene are not considered sufficient to induce abnormal cellular proliferation in the
absence of cooperating oncogenes. We demonstrate that the conditional expression of an endogenous K-rasG12D allele in
murine embryonic fibroblasts causes enhanced proliferation and partial transformation in the absence of further genetic
abnormalities. Interestingly, K-rasG12D-expressing fibroblasts demonstrate attenuation and altered regulation of canonical
Ras effector signaling pathways. Widespread expression of endogenous K-rasG12D is not tolerated during embryonic develop-
ment, and directed expression in the lung and GI tract induces preneoplastic epithelial hyperplasias. Our results suggest
that endogenous oncogenic ras is sufficient to initiate transformation by stimulating proliferation, while further genetic
lesions may be necessary for progression to frank malignancy.
Introduction et al., 1998; Lowe and Sherr, 2003; Serrano et al., 1997; Zindy
et al., 1998). The inability of ectopically expressed oncogenes
Oncogenes were originally characterized as transforming ge- to transform primary cells in culture is in contrast to several
netic elements contained within tumorigenic retroviruses (Ma- clinical observations in which preneoplastic cells harbor single
lumbres and Barbacid, 2003; Varmus and Bishop, 1986). How- oncogenic mutations in the absence of obvious cooperating
genetic events. For example, the Bcr-Abl translocation in stableever, the role of oncogenes in the initiation of cancer has
remained ambiguous. Indeed, ectopic expression of individual phase chronic myelogenous leukemia (Shet et al., 2002) and
K-ras mutations in pancreatic ductal hyperplasias (Moskalukoncogenes in primary cells does not promote transformation
without cooperating genetic events (Kamijo et al., 1997; Land et al., 1997) occur in cell populations that apparently lacked
additional oncogenic or p14ARF/p53 mutations. These findingset al., 1983; Ruley, 1983; Serrano et al., 1996; Tanaka et al.,
1994). Furthermore, retroviral transduction of oncogenes in pri- suggest that aberrant expression of ectopically introduced on-
cogenes confers different biological effects than endogenouslymary rodent or human cells does not stimulate proliferation,
but instead causes either growth arrest or apoptosis through expressed oncogenes.
Investigations into the role of oncogenes in tumorigenesisactivation of the p19ARF (p14ARF)/p53 pathway (de Stanchina
S I G N I F I C A N C E
Although the K-ras oncogene is mutated in a significant proportion of pancreatic, colon, and lung tumors, its role in the earliest
stages of neoplasia is unclear. Indeed, recent findings have demonstrated that the widespread expression of an endogenous
K-rasG12V-IRES-BGeo allele had no overt consequences in most tissues, supporting the premise that the role of oncogenic ras is restricted
to tumor progression. Using a different gene-targeting strategy, we generated a mutant mouse that harbors a conditional K-rasG12D
allele and found that widespread expression of K-rasG12D causes embryonic lethality, whereas directed expression stimulates abnormal
proliferation in tissues that harbor K-ras mutations in human cancer. Therefore, ras mutation may be a primary event in tumorigenesis,
highlighting the need to pursue anti-Ras therapies in preneoplastic conditions as well as in advanced malignancies.
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have often employed the ras gene family, due to the frequency Results
of ras mutations in human epithelial cancers (Bos, 1989). Gene-
K-rasG12D-expressing fibroblasts exhibit elevatedtic and biochemical analyses have established that Ras pro-
Ras-GTP levels and enhanced proliferativeteins function as plasma membrane-bound GTPases that are
properties, and not premature senescencestimulated by growth factor receptor tyrosine kinases and acti-
We recently described the construction of a conditionally ex-vate downstream effector pathways when bound to GTP (Scol-
pressing K-rasG12D mutant mouse using the Cre-Lox systemnick et al., 1979). Several Ras effector pathways, including the
(Jackson et al., 2001). Germline transmission of the conditionalRaf/MEK/ERK (MAPK) and PI3K/AKT kinase cascades, promote
K-ras allele (LSL-K-rasG12D; Figure 1A) was confirmed by South-cell proliferation, differentiation, and survival (Vojtek and Der,
ern blotting, and conditional heterozygous LSL-K-rasG12D/mu-1998). It has been proposed that the molecular basis of ras
rine embryonic fibroblasts (MEFs) and littermate wild-type MEFs
oncogenicity is constitutive effector pathway stimulation due to were prepared. Molecular and cellular properties were examined
ras missense mutations that stabilize the GTP-bound configu- 2 days after infecting early passage wild-type and littermate
ration of Ras by decreasing the intrinsic Ras-GTPase activity LSL-K-rasG12D/ MEFs with recombinant retroviruses encoding
and by conferring resistance to cellular proteins that allosteri- green fluorescent protein (GFP) or “self-excising” cre recombi-
cally stimulate Ras GTPase activity (Malumbres and Barbacid, nase (Silver and Livingston, 2001). The LSL-K-rasG12D MEFs
2003). demonstrated striking morphological alterations, including in-
Studies examining ras mutation as an initiating event in cellu- creased refractility and disruption of the actin cytoskeleton,
lar transformation have been hampered by the observation that within 2–3 days of viral-cre infection, when compared to unin-
mutant ras induces growth arrest in primary cells unless accom- fected conditional MEFs or uninfected and viral-cre infected
wild-type MEFs (Figure 1B and data not shown). Transductionpanied by cooperating oncogenes or coincident loss of func-
with a virus expressing GFP revealed greater than 95% infectiontional p53 or p19ARF pathways (Kamijo et al., 1997; Land et
efficiency, without accompanying morphological changes (dataal., 1983; Ruley, 1983; Serrano et al., 1997; Tanaka et al., 1994;
not shown). Examination of DNA, mRNA, and protein from theZindy et al., 1998). The growth arrest triggered by overexpres-
viral-cre infected LSL-K-rasG12D MEFs demonstrated that thesion of oncogenic H-ras has been termed “premature senes-
conditionally mutant K-ras allele was efficiently recombined andcence” because it mimics many aspects of cellular replicative
expressed at levels similar to the wild-type allele (Figures 1Csenescence (Serrano et al., 1997). Premature senescence has
and 1D) (Johnson et al., 2001). This K-rasG12D-expressing MEFbeen attributed to chronic hyperstimulation of the MAPK cas-
population will hereafter be designated Lox-K-rasG12D MEFs.cade (Lin et al., 1998; Zhu et al., 1998). However, most studies
Lox-K-rasG12D MEFs demonstrated elevated Ras-GTP levels in
of oncogenic ras function have utilized ras cDNA constructs
a Raf-GST pulldown assay (Figure 1E) (Taylor and Shalloway,
that direct supraphysiological expression levels. Additionally, 1996). To exclude the possibility that these results were due to
although K-ras is the ras family member most often mutated in genomic damage caused by the expression of cre recombinase
human cancer (Bos, 1989), mutant H-ras alleles have been used (Loonstra et al., 2001; Silver and Livingston, 2001), we per-
in most studies. formed spectral karyotyping (SKY) on MEFs infected with self-
To examine the signal transduction pathways, cellular prop- excising retroviral-cre. SKY analysis demonstrated no cytoge-
erties, and in vivo consequences conferred by physiological netic abnormalities after self-excising retroviral-cre infection
expression levels of oncogenic K-ras, we have extended our (N  10, data not shown), consistent with prior observations
analysis of a conditional K-rasG12D mutant mouse to primary (Silver and Livingston, 2001).
The cellular properties of Lox-K-rasG12D, LSL-K-rasG12D, andmouse embryonic fibroblasts (MEFs) and epithelial tissues. An
wild-type MEFs, passaged in parallel, were further evaluated inanalogous approach that utilized a bicistronic K-rasG12V-IRES-BGeo
standard proliferation assays. Lox-K-rasG12D MEFs demon-endogenous allele was recently reported (Guerra et al., 2003).
strated enhanced proliferation compared to control MEFs, par-The conditional K-rasG12D mice develop epithelial neoplasms
ticularly at high cell densities (Figure 2A). Additionally, althoughupon activation of endogenous K-rasG12D expression in the lung
none of the MEF populations proliferated in 0.5% serum, Lox-(Jackson et al., 2001) and pancreas (Hingorani et al., 2003). Here
K-rasG12D MEFs proliferated in 2% serum, whereas the otherwe find that K-rasG12D-expressing MEFs demonstrate enhanced
MEFs did not (Figure 2B). Cell cycle analysis with BrdU incorpo-proliferative properties, lack contact inhibition, and are immortal
ration of early-passage, asynchronously growing MEFs demon-despite having functional p19ARF and p53 pathways. Moreover,
strated an S phase content of 27% in Lox-K-rasG12D MEFs and
widespread embryonic expression of K-rasG12D is uniformly le-
15% in LSL-K-rasG12D MEFs (Figure 2C). These findings contrast
thal, whereas the spatially controlled expression of K-rasG12D with the ectopic overexpression of oncogenic H-ras in MEFs,
induces epithelial hyperplasias in vivo. Strikingly, K-rasG12D- which has been shown to cause a decreased S phase fraction
expressing fibroblasts and epithelial cells exhibit attenuation of and cell cycle arrest (Serrano et al., 1997).
the MAPK pathway, which may explain why they do not undergo Since much of the work describing Ras-induced senescence
premature cellular senescence. Furthermore, and in contrast to was performed with cDNA constructs expressing high levels
primary cells overexpressing oncogenic ras, MEFs expressing of the H-ras oncogene, we wished to determine whether the
endogenous levels of K-rasG12D cooperate with E1a, but not discrepancies between the earlier results and those observed
c-Myc, to achieve full transformation. Collectively, these results here were attributable to the type of ras oncogene used. Accord-
question the relevance of oncogenic ras-induced premature ingly, MEFs were evaluated following transduction with retrovi-
senescence and challenge the model of oncogene cooperation ruses encoding H-rasG12V and the 4A and 4B splice forms of
K-rasG12D (George et al., 1985). In contrast to the increased prolif-in the initiation of cellular transformation.
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Figure 1. Conditional K-rasG12D mouse strain and MEFs
A: Schematic of (i) STOP element, (ii) targeting vector, (iii) wild-type allele, (iv) LSL-K-rasG12D allele, and (v) Lox-K-rasG12D allele. B, BamH1; K, Kpn1/Acc651;
N; Not1; Xb, Xba1; SA, adenoviral splice acceptor site; *, GGT to GAT mutation at codon 12. The position of the probes for Southern blotting is shown (5,
INT  internal, 3). Arrows in v denote PCR primer sites for the recombination assay.
B: Morphological alterations and increased refractility in LSL-KrasG12D MEFs 72 hr after infection with self-excising retroviral-cre. Phase contrast (upper panels)
and actin cytoskeleton (lower panels, phalloidin Oregon-green  DAPI) are shown.
C: Efficient excision of the STOP cassette in cell culture. Southern blot analysis of Bam H1  Acc651 digested genomic DNA prepared from LSL-K-rasG12D
MEFs 72 hr after infection with retroviral-GFP (G) or retroviral-cre (C), using the 5 external probe. The wild-type allele and recombined Lox-K-rasG12D allele
are denoted by the 12 kb fragment, and the intact conditional LSL-K-rasG12D allele migrates as a 7 kb fragment.
D: The mutant K-rasG12D mRNA and protein is expressed only after infection of conditional MEFs with retroviral-cre. Wild-type and LSL-K-rasG12D MEFs were
either mock infected (M), infected with retroviral-GFP (G), or infected with retroviral-cre (C).
E: Ras-GTP levels are specifically elevated in Lox-K-rasG12D MEFs. Ras-GTP was recovered from MEFs with Raf-GST and glutathione-agarose. A loading control
for total Ras is shown below.
erative properties of Lox-K-rasG12D MEFs, growth inhibition was mortal, whereas LSL-K-rasG12D and wild-type MEFs senesced
after 5–10 passages (Figure 3A). The replicative immortality ofobserved in MEFs transduced with either H-rasG12V, K-ras 4AG12D,
or K-ras 4BG12D (data not shown). These constructs expressed Lox-K-rasG12D MEFs contrasts with the premature senescence
observed in MEFs overexpressing oncogenic H-ras (Serrano etapproximately 20, 5, and 5 fold more H-Ras, K-Ras 4A, and
K-Ras 4B, respectively, than control and Lox-K-rasG12D MEFs al., 1997) and K-ras (not shown). Additionally, confluent cultures
of Lox-K-rasG12D MEFs grew to an extremely high density and(Figure 2D). Furthermore, while MEFs ectopically overexpress-
ing either oncogenic H-ras or K-ras demonstrated a premature readily demonstrated loss of contact inhibition and focus forma-
tion after two to three weeks of continuous culture (Figure 3B).senescent morphology and contained elevated levels of sen-
escence-associated  galactosidase (SA-gal) activity, Lox- Nevertheless, Lox-K-rasG12D MEFs were unable to form colonies
when cultured at very low density or grown in semisolid media,K-rasG12D MEFs did not (Figure 2E). Consistent with these results,
the levels of p19ARF and p53, two proteins known to mediate and were not tumorigenic in nude mice (data not shown).
Since ectopic expression of oncogenic ras cooperates withoncogenic ras-induced growth arrest, were both noticeably
higher in MEFs overexpressing oncogenic ras compared to con- several other oncogenes and p53 pathway deficiency to pro-
mote the transformation of primary cells (Land et al., 1983;trol and Lox-K-rasG12D MEFs (Figure 2F). Hence, the difference
between the earlier results and those represented here cannot Ruley, 1983; Tanaka et al., 1994), we assessed Lox-K-rasG12D
MEFs for similar effects. Notably, the proliferation of Lox-be attributed to the use of different ras oncogenes.
K-rasG12D MEFs was increased only slightly following retroviral
transduction of c-Myc (Figure 3C), but was greatly increasedLox-K-rasG12D MEFs are partially transformed
when transduced with adenoviral E1a (Figure 3D) or by p53Lox-K-rasG12D MEFs were further characterized with standard
immortalization and transformation assays. Serial passaging re- deficiency (Figure 3E). p53 absence, and to a lesser extent E1a
expression, permitted anchorage-independent growth of Lox-vealed that multiple lines of Lox-K-rasG12D MEFs (3/3) were im-
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Figure 2. Lox-K-rasG12D MEFs have enhanced proliferation and are not senescent
A: Enhanced proliferation in MEFs expressing endogenous levels of oncogenic K-ras. Wild-type (open symbols) and LSL-K-rasG12D (filled symbols) MEFs were
mock infected (diamonds), viral-GFP infected (squares), or viral-cre infected (triangles).
B: Lox-K-rasG12D MEFs proliferate in limiting serum. MEFs were as described in A, and cultured in the presence of media supplemented with 2% or 0.5% serum.
C: Increased S phase by BrdU incorporation and FACS analysis in asynchronously proliferating Lox-K-rasG12D MEFs compared to LSL-K-rasG12D MEFs.
D: Relative Ras protein levels following transduction of LSL-K-rasG12D MEFs with no virus (M), viral-cre (C), empty vector (), oncogenic H-rasG12V (H), K-ras
4AG12D (4A), and K-ras 4BG12D (4B).
E: Ectopic but not endogenous expression of oncogenic ras leads to premature senescence. SA-gal levels are increased in MEFs ectopically expressing
oncogenic ras, but not Lox-K-rasG12D MEFs. Phase contrast and bright field micrographs are shown at 200magnification. SA-gal positive cells were counted
( SEM) 5 days after transduction. Symbols are as in D.
F: Elevated levels of p19ARF and p53 in oncogenic ras overexpressing MEFs compared to Lox-K-rasG12D MEFs and control MEFs. Wild-type and LSL-K-rasG12D
MEFs were either mock treated (M) or infected with GFP-virus (G) or cre-virus (C). Alternatively, LSL-K-rasG12D MEFs were transduced with empty (), H-rasG12V
(H), K-ras4aG12D (4A), or K-ras4BG12D (4B) viruses.
K-rasG12D MEFs, whereas c-Myc expression did not (Figure 3F). inability of Lox-K-rasG12V-IRES-BGeo MEFs to form foci or cooperate
with E1a in standard transformation assays (Guerra et al., 2003).Unexpectedly, and in contrast to the cotransfection of primary
cells with ras and myc, examination of the soft agar cultures of
Lox-K-rasG12D MEFs transduced with c-Myc revealed evidence Cell cycle activation in Lox-K-rasG12D MEFs
To investigate the molecular pathways responsible for the mark-of adipoctye differentiation as indicated by the Oil Red O staining
of refractile, lipid-laden cells (Figure 3F). Lastly, Lox-K-rasG12D edly different proliferative properties of the MEF populations
described above, protein lysates from early passage cells wereMEFs lacking p53 were tumorigenic in vivo (N  6/6), whereas
Lox-K-rasG12D MEFs transduced with E1a or c-Myc were not prepared and immunoblotted with antibodies against specific
cell cycle regulatory components (Figure 4A). Lox-K-rasG12D(N  0/6, data not shown). Thus, endogenous K-rasG12D expres-
sion did not cooperate with c-Myc for cellular transformation, MEFs contained elevated Cdk2, cyclin A, cyclin E, cyclin D1,
p21, and p16 protein levels compared to control MEFs, whereasand cooperated to a limited extent with ectopic E1a expression
and fully with p53 deficiency to transform MEFs, in contrast to oncogenic ras overexpressing MEFs contained increased cyclin
D1, p21, and p16 levels, but decreased cyclin A and cyclin Egenetic cooperation experiments with primary cells that ectopi-
cally express oncogenic ras. These results contrast with the levels. The levels of cyclin D2, Cdk4, and p27 were not signifi-
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Figure 3. Lox-K-rasG12D MEFs are partially trans-
formed
A: Lox-K-rasG12D MEFs are immortal in a 3T3 assay.
3T3 assay of three independent Lox-K-rasG12D MEF
lines (filled symbols) and the corresponding LSL-
K-rasG12D MEFs (open symbols), with population
doublings (ordinate) plotted against the pas-
sage number (abscissa). The onset of senes-
cence (arrow) and immortalization (dashed
arrow) are denoted in the LSL-K-rasG12D MEFs.
B: Loss of contact inhibition in Lox-K-rasG12D MEFs.
MEFs were grown to confluency, and the media
was replenished each day until foci were evident
(14–21 days). Foci were demonstrated by fixation
and staining with Giemsa (arrow).
C: C-Myc slightly increases the proliferation of
Lox-K-rasG12D MEFs. Wild-type MEFs (diamonds)
and two independent lines of Lox-K-rasG12D MEFs
(squares and triangles) were transduced with
empty vector (open symbols) or c-Myc (filled
symbols).
D: E1a greatly increases proliferation of Lox-
K-rasG12D MEFs. Wild-type MEFs (diamonds) and
two independent lines of Lox-K-rasG12D MEFs
(squares and triangles) were transduced with
empty vector (open symbols) or E1a (filled
symbols).
E: P53 loss greatly increases proliferation of Lox-
K-rasG12D MEFs. P53/ MEFs (open symbols) and
p53/;LSL-K-rasG12D MEFs were either mock in-
fected (diamonds) or transduced with viral-GFP
(squares) or viral-cre (triangles).
F: P53 loss and E1a synergize with K-rasG12D for
anchorage-independent growth in MEFs. Soft
agar assay demonstrates effects of c-Myc, E1a,
and p53 loss alone (upper panels) and in the
setting of K-rasG12D expression (lower panels). Adi-
pocyte differentiation in c-Myc-transduced Lox-
K-rasG12D MEFs is demonstrated by Oil Red O stain-
ing (arrow).
cantly different between the cell types. To determine whether pharmacological inhibitors of the MAPK and PI3K pathways,
U0126 and LY294002, respectively, indicated that these path-the alterations in the cell cycle machinery in Lox-K-rasG12D MEFs
conferred increased enzymatic activity in cyclin dependent ki- ways contribute to the morphological changes seen in Lox-
K-rasG12D MEFs (Figure 5B). Additionally, the DNA binding activitynase complexes, we assessed Cdk2 and Cdk4 in vitro kinase
of ELK-1, a transcription factor activated by the MAPK cascade,activities in asynchronously proliferating MEFs (Matsushime et
was increased in nuclear extracts of Lox-K-rasG12D MEFs com-al., 1994). Notably, Lox-K-rasG12D MEFs had 2–4 fold increases
pared to control MEFs (Figure 5C). Therefore, the MAPK andin Cdk2 and Cdk4 in vitro kinase activities compared to LSL-
PI3K cascades can be found to be activated in Lox-K-rasG12DK-rasG12D MEFs (Figure 4B). Importantly, the increased Cdk2 and
MEFs and may be important for some aspects of their pheno-Cdk4 in vitro kinase activity in Lox-K-rasG12D MEFs contrasts
type. However, in exponentially growing cells, the steady statewith the decreased Cdk2 activity demonstrated in MEFs overex-
levels of the activated components of these pathways are notpressing oncogenic H-ras (Serrano et al., 1997), and provides a
increased.potential explanation for the distinct proliferative characteristics
To determine whether the activation of the MAPK and PI3Kamong the cell populations assessed here.
cascades by wild-type Ras-GTP was augmented in cells that
express endogenous levels of Lox-K-rasG12D, LSL-K-rasG12DAttenuation of Ras effector pathway signaling
in Lox-K-rasG12D MEFs MEFs and Lox-K-rasG12D MEFs were grown to confluency, serum
starved, and restimulated, and protein lysates prepared. Consis-The activation of the well-characterized Ras effector pathways,
MAPK and PI3-kinase (PI3K), was assessed by preparing whole tent with the observations from exponentially growing cells,
phosphorylation of MEK and AKT in response to serum stimula-cell lysates from subconfluent MEFs and immunoblotting with
phosphorylation state-specific anti-ERK 1/2 and anti-AKT anti- tion was found to be attenuated in Lox-K-rasG12D MEFs com-
pared to LSL-K-rasG12D MEFs (Figure 5D). Similar results werebodies. While MEFs ectopically overexpressing oncogenic ras
had elevated levels of phosphorylated ERK 1/2 and phosphory- obtained with phosphorylated ERK 1/2 (data not shown). Addi-
tionally, the ERK (Figure 5E) and AKT (Figure 5F) in vitro enzy-lated AKT, Lox-K-rasG12D MEFs unexpectedly contained equal
or even decreased levels compared to LSL-K-rasG12D and wild- matic activities were also diminished following serum stimula-
tion in Lox-K-rasG12D MEFs compared to LSL-K-rasG12D MEFs.type MEFs (Figure 5A). Despite this observation, the use of
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Lox-K-rasG12D MEFs were sensitive to the effects of ras overex-
pression, Lox-K-rasG12D MEFs and p53/ MEFs were trans-
duced with oncogenic K-ras and H-ras and examined for prolif-
erative capacity and signaling pathways. Following transduction
with oncogenic ras, Lox-K-rasG12D MEFs demonstrated a de-
creased growth rate and a premature senescent morphology;
in contrast, p53/ MEFs continued to proliferate (Figure 6A
and data not shown), as previously described (Serrano et al.,
1997; Tanaka et al., 1994). Additionally, protein lysates from
oncogenic ras overexpressing Lox-K-rasG12D MEFs contained
increased p19ARF, p53, and phosphorylated ERK 1/2 levels
(Figure 6B). This result confirms that the cellular characteristics
of Lox-K-rasG12D MEFs are dependent upon the lower endoge-
nous expression level of oncogenic K-ras than the levels di-
rected by retroviral transduction.
To assess the function of the p53 pathway, Lox-K-rasG12D
MEFs and LSL-K-rasG12D MEFs were incubated with 0.2 g/ml
adriamycin, and cells and protein lysates were serially collected
over a 20 hr time course. Following 20 hr of treatment, both
Lox-K-rasG12D MEFs and LSL-K-rasG12D MEFs arrested in G1 and
G2/M with no cells remaining in the S phase of the cell cycle
(Figure 6C). As previously demonstrated (Figures 2F and 4A),
the p53 and p21 protein levels were higher in the Lox-K-rasG12D
MEFs than the LSL-K-rasG12D MEFs prior to adriamycin incuba-
tion (Figure 6D). Following adriamycin treatment, the magnitude
of increase of p53 and p21 protein levels was similar between
Figure 4. Cell cycle pathway activation in Lox-K-rasG12D MEFs the two populations of MEFs, suggesting a similar sensitivity to
genotoxic stress (Figure 6D). Thus, the p19ARF/p53 pathwayA: Levels of cell cycle associated proteins in whole cell lysates. Wild-type
(Wt) and LSL-K-rasG12D MEFs were either mock infected (M) or transduced appears to be intact in the Lox-K-rasG12D MEFs, as has been
with viral-cre (C). Additionally, MEFs were transduced with empty vector demonstrated in Lox- K-rasG12V-IRES-BGeoMEFs (Guerra et al., 2003).
(), H-rasG12V (H), murine K-ras 4AG12D (4A), or murine K-ras 4BG12D (4B).
B: Elevated Cdk2 and Cdk4 in vitro kinase activities. Rabbit 	 globulin (Rgg),
Expression of endogenous oncogenic K-rasG12D duringgoat 	 globulin (Ggg), and Cdk2 and Cdk4 immunoprecipitates were pre-
murine development results in widespread morphologicalpared from LSL-K-rasG12D MEFs that were either mock infected (M) or viral-
cre (C) infected. In vitro kinase activities were evaluated with recombinant aberrations and early embryonic lethality
pRb as the substrate. The effects of embryonic expression of K-rasG12D were assessed
in mice by interbreeding the conditional LSL-K-rasG12D mice with
Protamine-Cre (PrmCre) and CMV-cre mice.
The mouse protamine 1 promoter is active in haploid sperm,
Similar analyses of MEFs that ectopically overexpressed leading to efficient cre-mediated recombination in the male germ
H-rasG12V did not demonstrate any attenuation of Ras effector line (O’Gorman et al., 1997), and the CMV-cre transgene is
pathway signaling (Supplemental Figure S1 at http://www. active in mosaic fashion during development (Schwenk et al.,
cancercell.org/cgi/content/full/5/4/375/DC1). Thus, the activa- 1995). Male offspring bearing both the PrmCre transgene and
tion of the PI3K and MAPK cascades by serum stimulation the conditional LSL-K-rasG12D allele were thus mated to wild-
is regulated differently in Lox-K-rasG12D MEFs as compared to type females, and genotyping revealed no viable Lox-K-rasG12D
control MEFs and MEFs overexpressing oncogenic ras, perhaps progeny. An analysis of over 100 embryos ranging in age from
reflecting the adaptation of cells that harbor endogenous alleles 8.5 days old (E8.5) to E18.5 identified 30 which harbored the
of oncogenic K-ras. These results are particularly interesting as recombined allele; however, none were viable past E11.5. Mu-
the MAPK cascade had been previously implicated as the Ras tant embryos were characteristically small and pale (Figures 7A
effector pathway responsible for premature senescence (Lin et and 7B), and microscopic analysis of E9.5 mutant embryos
al., 1998; Serrano et al., 1997; Zhu et al., 1998), and suggest showed cardiomegaly and abnormal brain development (Fig-
that ectopic expression of oncogenic ras generates constitutive, ures 7C and 7D). At the cellular level, neuroepithelial sections
high-level MAPK cascade activation that cannot be appropri- revealed extensive areas of architectural distortion and apopto-
ately modulated in primary cells. sis (Figures 7E and 7F). Additionally, and in contrast to Guerra
and colleagues, we were unable to produce any CMV-cre;LSL-
Intact p19ARF/p53 pathway in Lox-K-rasG12D MEFs K-rasG12D mice, or CMV-cre;Lox- K-rasG12D mice, and an embryo-
The p19ARF/p53 pathway is commonly inactivated during im- logical assessment of this cross is in progress. These findings
mortalization in murine cells (Harvey and Levine, 1991; Kamijo demonstrate that widespread or germline embryonic expression
et al., 1997), and the overexpression of oncogenic ras can trans- of an endogenous K-rasG12D allele is uniformly lethal.
form cells with mutations in this pathway (Kamijo et al., 1997;
Serrano et al., 1996; Tanaka et al., 1994). Thus, it was important Induction of epithelial hyperplasias by K-rasG12D
to know the state of this pathway in Lox-K-rasG12D MEFs. In To extend our analysis of endogenous K-rasG12D function to spe-
cific epithelial tissues in vivo, the LSL-K-rasG12D allele was condi-order to stimulate p19ARF expression and evaluate whether the
380 CANCER CELL : APRIL 2004
A R T I C L E
Figure 5. Modulation of Ras effector pathways in Lox-K-rasG12D MEFs
A: Levels of phosphorylated ERK and AKT in control MEFs, Lox-K-rasG12D MEFs, and oncogenic ras-overexpressing MEFs.
B: Reversion of morphological alterations in Lox-K-rasG12D MEFs by MEK and PI3K inhibition. MEFs were cultured in the presence of either 0.1% DMSO, 10 uM
U0126, or 50 uM LY294002 for 24 hr before fixation and staining with phalloidin-Oregon green and DAPI.
C: ELK-1 activity is increased in Lox-K-rasG12D MEFs. Nuclear extracts were prepared from multiple lines of LSL-K-rasG12D MEFs (lanes 1 and 2) and Lox-K-rasG12D
MEFs (lanes 3–5), and EMSA performed. The retarded migration of the ELK-1 probe and migration of the free probe is shown. Incubation with cold competitor
ELK oligonucleotide is shown in lane 5.
D: Diminished activation of MEK and AKT following serum stimulation of Lox-K-rasG12D MEFs compared to LSL-K-rasG12D MEFs. MEFs were grown to confluency,
serum starved for 24 hr, and stimulated for various times with normal media before preparation of protein lysates and immunoblotting. Anti-phosphorylated
and total MEK and AKT antibodies were used. Similar results were obtained with anti-phospho ERK (data not shown).
E and F: ERK (E) and AKT (F) in vitro kinase reactions from cells treated as described in D.
tionally activated in the lung and gastrointestinal tract. Pulmo- gesting that other genetic events are not required. The prolifera-
tive nature of these lesions was supported by the elevatednary hyperplasias were induced by the nasal instillation of
adenoviral-cre (Jackson et al., 2001) within 4 days of infec- nuclear immunostaining with Ki-67 (17.5  2.5%, compared
with 2.6 0.6% in control pulmonary tissue). Additionally, intra-tion (Supplemental Figure S2 at http://www.cancercell.org/cgi/
content/full/5/4/375/DC1, Figure 8A), demonstrating that prolif- nuclear cyclin D1 was detected in the hyperplasias, consistent
with its postulated role in stimulating proliferation. As a positiveeration in vivo closely parallels K-rasG12D expression and sug-
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Figure 6. Intact p19ARF and p53 pathways in Lox-
K-rasG12D MEFs
A: Overexpression of oncogenic ras causes pre-
mature senescence of Lox-K-rasG12D MEFs. Lox-
K-rasG12D MEFs were transduced with empty vec-
tor (), H-rasG12V (H), K-ras 4AG12D (4A), or K-ras
4BG12D (4B) and assessed for SA-gal positivity
( SEM) as in Figure 2E.
B: Overexpression of oncogenic ras causes hy-
peractivation of ERK and elevated p19ARF and
p53 protein levels in Lox-K-rasG12D MEFs.
C: Intact p53 response in LSL-K-rasG12D and Lox-
K-rasG12D MEFs. MEFs were incubated with 0.2
g/ml adriamycin for 20 hr, and cell cycle analy-
sis was performed.
D: p53 and p21 induction from genotoxic stress.
LSL-K-rasG12D and Lox-K-rasG12D MEFs were incu-
bated with 0.2g/ml adriamycin (Sigma) for vari-
ous lengths of time, and p53 and p21 protein
levels were assessed by immunoblotting.
control for ERK activation in vivo, phosphorylated ERK1/2 was sias are markedly different from the reported lack of effect of
an expressed K-rasG12V-IRES-BGeo allele in colonic epithelial cellsdetectable in primitive spermatogonia and primary spermato-
cytes—cells known to contain elevated phosphorylated ERK (Guerra et al., 2003).
We have recently reported that the expression of endoge-1/2 levels (Lu et al., 1999). However, phosphorylated ERK 1/2
was not detectable by this method in the pulmonary hyperpla- nous K-rasG12D in the exocrine pancreas induces proliferative
pancreatic intraepithelial neoplasms (PanIN) as early as twosias. Pulmonary hyperplasias and neoplasms were also reported
with the bitransgenic CMV-cre;LSL- K-rasG12V-IRES-BGeo mice (Guerra weeks of age (Hingorani et al., 2003). These findings significantly
differ from the lack of effect of an expressed K-rasG12V-IRES-BGeoet al., 2003), although the latency between expression of the
endogenous K-rasG12V-IRES-BGeo allele and pulmonary epithelial hy- allele in pancreatic epithelial cells unless a concomitant
CDK4R24C mutation is present (Guerra et al., 2003). Additionalperplasia was not reported.
The effects of endogenous K-rasG12D expression in colonic studies with other transgenic-cre mice have revealed skin papil-
lomas in the background of a K14-creER allele (Vasioukhin etepithelial cells were examined by interbreeding LSL-K-rasG12D
mice with fatty acid binding protein (Fabp)-cre transgenic mice al., 1999), submandibular gland hyperplasia (Supplemental Fig-
ure S4) in the background of an MMTV-cre allele (Wagner et(Saam and Gordon, 1999). All LSL-K-rasG12D;Fabp-cre com-
pound mice examined (14/14) had diffuse hyperplasia and dys- al., 1997), and a fatal myeloproliferative disorder in the setting
of an Mx1-cre allele (Braun et al., 2004; Chan et al., 2004) (seeplasia of the colonic crypts that was obvious by 4 weeks of
age, whereas the parental strains did not (Figure 8B and Supple- Supplemental Data at http://www.cancercell.org/cgi/content/
full/5/4/375/DC1).mental Figure S3). Evidence of increased proliferation in the
hyperplastic and dysplastic colonic epithelium was demon- To investigate whether ras-induced senescence occurs fol-
lowing K-rasG12D expression in vivo, lung, colonic, and pancreaticstrated by Ki-67 immunostaining in nuclei located distant from
the base of the colonic crypts (Figure 8B and Supplemental tissue was immunohistochemically evaluated for the levels of
p53, p16Ink4a, p19ARF, and p21 proteins. Neither normal norFigure S3). Consistent with the results of K-rasG12D expression
in pulmonary hyperplasias, phosphorylated ERK 1/2 was again hyperplastic portions of epithelial tissue contained detectable
levels of these proteins, suggesting that ras-induced senes-not detectable. In contrast to the pulmonary hyperplasias, cy-
clin D1 could not be detected in these colonic hyperplasias cence was not occurring by these criteria in vivo (D.A.T., un-
published data). An additional approach was undertakenfor unknown reasons. These epithelial hyperplasias and dyspla-
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Discussion
Enhanced proliferation and partial transformation
by endogenous K-rasG12D
We show that the endogenous expression of K-rasG12D stimulates
the proliferation of MEFs in contrast to the growth arrest ob-
served in primary cells expressing ectopic oncogenic ras (Ser-
rano et al., 1997). Lox-K-rasG12D MEFs have elevated levels of
Cdk2, cyclin A, cyclin E, and cyclin D1, and increased Cdk2
and Cdk4 activities in vitro, consistent with the augmented pro-
liferation of these cells. Conversely, the growth arrest induced
in primary cells by ectopically expressed oncogenic ras is char-
acterized by decreased Cdk2 activity in the setting of decreased
cyclin A levels and elevated cyclin D1, p21, and p16 levels
(Serrano et al., 1997). However, overexpressed H-rasG12V also
induces growth arrest in p21/, p21/;p27/, and p16/
primary MEFs (Groth et al., 2000; Pantoja and Serrano, 1999;
Sharpless et al., 2001), suggesting the involvement of still other
mediators in oncogenic ras-induced growth arrest. Indeed
p19ARF, a gene expressed in response to ectopically intro-
duced mutant ras and other oncogenes (de Stanchina et al.,
1998; Zindy et al., 1998), activates p53 through the inhibition
of mdm2 (Kamijo et al., 1998; Pomerantz et al., 1998; Zhang et
al., 1998) and causes growth arrest in both cyclin D/Cdk4-
dependent and -independent fashions (Groth et al., 2000). Fur-
thermore, p19ARF is required for ectopic oncogenic ras-
induced senescence (Kamijo et al., 1997; Lowe and Sherr, 2003).
Notably, Lox-K-rasG12D MEFs have lower p19ARF and p53 levels
compared to MEFs overexpressing oncogenic ras, and Lox-
K-rasG12D MEFs are not growth arrested but rather demonstrate
Figure 7. Embryologic consequences of expressing endogenous levels of
increased proliferation in limiting serum and at high cell density.oncogenic K-rasG12D in the mouse germline
The loss of contact inhibition is an archetypal characteristicA: Normal external appearance of wild-type 9.5 day old (E9.5) embryos.
of fully transformed cells (Stoker and Rubin, 1967), and is wellOriginal magnification 60.
B: Marked developmental abnormalities of Lox-K-rasG12D E9.5 embryos. Com- documented in both immortal cell lines following the introduc-
pared to its littermate in A, the mutant embryo is smaller and pale, with an tion of oncogenic ras (reviewed in Malumbres and Barbacid,
open neural tube and cardiomegaly. Same magnification as in A.
2003) and primary cells cotransfected with oncogenic ras andC: Normal histology of wild-type E9.5 embryos. Shown is an H&E stained
parasagittal section. Original magnification 40. c-Myc (Land et al., 1983). The Lox-K-rasG12D MEFs described
D: Histological analysis of Lox-K-rasG12D E9.5 mouse embryos. H&E staining of here support focus formation, yet are very different from pre-
parasagittal sections reveals areas of gross morphologic changes in the viously described ras-transformed cells in several ways. First,
heart and developing neuraxis. Same magnification as in C.
in contrast to ectopic oncogenic ras-transformed cells, Lox-E: High-power magnification (1000) of neuroepithelium from the wild-type
E9.5 embryo shown in C. K-rasG12D MEFs cannot form colonies when cultured at low den-
F: High-power magnification (1000) of neuroepithelium from the mutant sity or when grown in semisolid media, and they are not tumori-
E9.5 embryo shown in D. Note the abundant mitotic figures (arrows) and
genic. Second, the subculturing of “foci” from cell layers didnumerous pyknotic and fragmented nuclei characteristic of apoptotic cell
not reveal any subpopulations of cells that were fully trans-death (arrow heads).
Abbreviations: H, heart; FB, forebrain; MB, midbrain; HB, hindbrain; O, otic formed (data not shown) and that could represent clonal events
pit; S, somites; SC, spinal cord. such as biallelic p19ARF loss or p53 mutation (Zindy et al., 1998).
Finally, since Lox-K-rasG12D MEFs grew to very high densities, we
hypothesized that focus formation was an intrinsic characteristic
of all MEFs that express endogenous levels of K-rasG12D in thewith pancreatic lysates prepared from bitransgenic LSL-K-
presence of functional p19ARF and p53 pathways, and as-rasG12D;p48/cre mice. These mice express oncogenic K-ras in
sessed the frequency of focus formation through the serial dilu-every epithelial cell of the pancreas, and the direct assessment
tion of Lox-K-rasG12D MEFs in coculture experiments with a fixedof p53, p16Ink4a, and p21 levels failed to reveal any increased
number of wild-type MEFs. These mixing experiments revealedlevels of these proteins (Supplemental Figure S5), suggesting
a frequency of focus formation of 1%–2% for Lox-K-rasG12Dthat ras-induced senescence is not a prominent feature of this
MEFs, and an only slightly higher frequency of 4%–5% for fullymodel. Collectively, these results demonstrate that the endoge-
transformed Lox-K-rasG12D;p53/MEFs (data not shown). Takennous expression of K-rasG12D in vivo confers significantly different
together, these results suggest that the formation of foci is aproperties in most tissues than the endogenous expression of
cell autonomous property of Lox-K-rasG12D MEFs and does notK-rasG12V-IRES-BGeo, even in tissues that do not normally harbor
K-ras mutations in human tumors, such as the salivary gland. represent individual clonal events.
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Figure 8. Proliferative and signaling properties of K-rasG12D-expressing hyperplasias
A: Pulmonary hyperproliferative lesions (hematoxylin & eosin, 200) in LSL-K-rasG12D mice 2 weeks after infection with adenoviral-cre demonstrate increased
intranuclear Ki-67 and cyclin D1 levels but not phosphorylated ERK 1/2 compared to similarly treated wild-type mice. Testicular tissue demonstrates primitive
spermatogonia and primary spermatocytes with elevated phosphorylated ERK 1/2 (arrow).
B: Hyperplastic and dysplastic colonic epithelium in bitransgenic Fabp-cre;LSL-K-rasG12D mice but not Fabp-cre mice. Increased numbers of Ki-67 positive
nuclei are found away from the crypts of the bitransgenic mice (arrow). Neither cyclin D1 nor phosphorylated ERK 1/2 could be detected in either genetic
background.
C: Molecular evidence of K-rasG12D mRNA expression in target tissues. Colonic tissue was isolated from LSL-K-rasG12D (lane 1) and LSL-K-rasG12D;Fabp-cre mice (lane
2), and lung tissue was isolated from LSL-K-rasG12D mice before (lane 3) and 4 weeks after (lane 4) adenoviral-cre infection. RNA was prepared, reverse
transcribed, amplified by PCR, and probed with K-rasG12 or K-rasG12D probes.
Absence of premature senescence and Ras effector following serum starvation and restimulation was suppressed
in Lox-K-rasG12D MEFs, but not in MEFs ectopically overexpress-pathway modulation in Lox-K-rasG12D MEFs
Oncogenic ras-induced premature senescence is caused by the ing H-rasG12V, suggesting that the MAPK and PI3K cascades
can be attenuated only when oncogenic ras is expressed atsustained hyperactivation of the MAPK pathway (Lin et al., 1998;
Zhu et al., 1998). In this study, we demonstrate that K-rasG12D- physiological levels and offering an explanation for the previous
difficulty in detecting pathway activation in Lox-K-rasG12D MEFs.expressing MEFs and epithelial hyperplasias exhibit neither fea-
tures of premature senescence nor evidence of MAPK hyperac- The inability to detect elevations of phosphorylated ERK 1/2
levels was not restricted to Lox-K-rasG12D MEFs, as K-rasG12D-tivation, but rather MAPK cascade attenuation. Additionally,
although Lox-K-rasG12D MEFs are “immortal” when assessed by expressing pulmonary and colonic epithelial hyperplasias also
lacked immunohistochemical evidence of this activated signal-serial passaging, they remain susceptible to premature senes-
cence when transduced with oncogenic H-ras or K-ras, and ing intermediate. Currently, the mechanisms of Ras effector
pathway attenuation are unclear, and preliminary investigationssuch senescence is accompanied by hyperactivation of the
MAPK pathway. The dependency of both premature senes- have not revealed any differences in the protein levels of Raf,
MEK, ERK, PI3-kinase, or AKT. Collectively, our data demon-cence and hyperactivation of the MAPK pathway on supraphysi-
ological expression levels of oncogenic ras suggests that neither strate that Ras effector pathway signaling that accompanies
endogenous expression levels of oncogenic K-rasG12D is notmay be important aspects of endogenous oncogenic ras func-
tion (Lowe and Sherr, 2003). Finally, the lack of increased levels reliably assessed by the isolated analysis of phosphorylated
ERK or phosphorylated AKT levels, a finding that may be rele-of p53, p16Ink4a, p19ARF, and p21 in lung, colon, and pancre-
atic tissues suggests that the predominant response in epithelial vant to the evaluation of Ras pathway inhibitors in clinical trials.
cells that express the K-rasG12D allele is to initiate proliferation
and not senescence in vivo. Initiation of transformation by endogenous K-rasG12D
may not require additional genetic eventsThe Ras effector pathways have previously been examined
almost exclusively in the context of transient transfection experi- Transformation of primary murine fibroblasts with ectopically
expressed oncogenic ras requires a cooperating oncogenements that employed supraphysiological levels of oncogenic
Ras. In contrast with the ease of identifying such signaling (Land et al., 1983; Ruley, 1983). Our evidence, however, sug-
gests that the endogenous expression of K-rasG12D alone is suf-events following the ectopic expression of oncogenic ras, evi-
dence of Ras effector pathway activation in Lox-K-rasG12D MEFs ficient to initiate the transformation of MEFs in cell culture and
to stimulate epithelial proliferation in vivo within several dayswas detected only after employing specific pharmacological
inhibitors of MEK and PI3K and assessing nuclear extracts for after the action of cre recombinase. First, the onset of K-rasG12D
expression coincides with morphological alterations and en-ELK-1 activity. Interestingly, the activation of ERK and AKT
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hanced proliferation in MEFs and alveolar epithelial cells (Figure K-rasG12V expression alone is tolerated with no overt conse-
quences in most tissues, including the colonic and pancreatic1 and Supplemental Figure S2). Second, spectral karyotyping
(SKY) analysis was undertaken on Lox-K-rasG12D MEFs, since epithelium. While we cannot exclude that oncogenic K-ras ex-
pression may be tolerated in certain tissues, we find that wide-karyotypic alterations such as c-Myc translocation have been
described in other immortal cell lines (Elenbaas et al., 2001). spread expression of K-rasG12D during embryogenesis is not tol-
erated, whereas the expression of K-rasG12V-IRES-BGeo does notImportantly, SKY revealed normal cytogenetic profiles in all ten
metaphase spreads examined from Lox-K-rasG12D MEFs (data preclude embryonic development. Also, we demonstrate that
expression of the K-rasG12D allele in colonic epithelium causesnot shown). Third, because ectopically expressed oncogenic
ras is known to cooperate with p19ARF loss (Kamijo et al., 1997) epithelial hyperplasia and dysplasia with total penetrance, and
or p53 mutation (Tanaka et al., 1994), the integrity of these recently reported that expression of K-rasG12D in pancreatic epi-
pathways was assessed in K-rasG12D MEFs. Examination of Lox- thelium induces pancreatic intraepithelial neoplasms (Hingorani
K-rasG12D MEFs failed to reveal functional deficiencies in p19ARF et al., 2003), whereas Guerra and colleagues could only show
or p53 in response to oncogenic ras overexpression or geno- pancreatic ductal metaplasia in cooperation with the CDK4R24C
toxic stress, respectively. Although we cannot exclude the pos- mutation. Finally, the analysis of the expression of K-rasG12D in
sibility that undetectable genomic damage due to cre recombi- multiple other tissue types suggests that this allele has prolifera-
nase contributes to the cellular phenotypes we describe here, tive effects in additional tissues such as the salivary gland, skin,
this is unlikely due to the absence of heterogeneous behavior and hematopoietic system (Braun et al., 2004; Chan et al., 2004).
in the Lox-K-rasG12D MEFs, and the lack of similar phenotypes Possible explanations for the discrepancy between our two
in control MEFs infected with viral-cre. studies include different molecular properties between the
K-rasG12V and K-rasG12D proteins, and differences in genetic back-
Oncogene cooperativity and tumorigenesis grounds. An additional possibility is the altered regulation of
The premise that ras gene mutations play a pivotal role in cellular expression and splicing of the K-rasG12V-IRES-BGeo allele as com-
transformation and tumorigenesis is based upon the high fre- pared to the K-rasG12D allele, since the former allele is a bicistronic
quency of ras mutations in human cancer and the transforming allele and contains a 3 BGeo reporter transgene. Future investi-
capability of mutant ras in immortal cell lines. The landmark gations will be needed to address these possibilities.
studies describing oncogene cooperativity demonstrated a re- Numerous models of cellular transformation and cancer
quirement for both ras and either c-Myc or E1A to transform have been developed through the introduction of oncogenes
primary cells (Land et al., 1983; Ruley, 1983). However, c-Myc into cells and animals. The ability of these systems to faithfully
appears to select for p53 deficiency and thereby enables over- model human disease, however, depends critically on recapitu-
expressed ras to induce proliferation rather than growth arrest lating physiological conditions as closely as possible. To this
(Zindy et al., 1998); E1A may function similarly (de Stanchina end, systems relying on ectopic overexpression of oncogenes
et al., 1998). Indeed, in the presence of an intact p19ARF/ may activate or suppress pathways not normally involved in
p53 pathway, high levels of ras expression induce senescence cognate human conditions harboring the very same endoge-
(Serrano et al., 1997). We find that the lower, physiological levels nous mutations and may therefore be more obfuscatory than
of mutant Ras do not activate the p19ARF/p53 pathway to the revealing. In this study, we have found that physiological expres-
same extent as primary cells overexpressing oncogenic ras, and sion of an activating K-rasG12D mutation can by itself partially
can instead promote proliferation in primary fibroblasts in culture transform MEFs and initiate tumorigenesis in animals. Our re-
and epithelial cells in vivo despite a lack of obvious cooperating sults contrast both with the presumed requirement for oncogene
events. Thus, cooperativity may be a requirement only in the cooperativity to achieve such effects, and the reported induction
context of ras overexpression. These findings explain how point of senescence in primary cell cultures by ectopic expression of
mutated ras can serve as an initiating event in human malig- activated ras. We propose, therefore, that the specific patterns
nancy, and, while less common, ras gene amplification or over- of activated and suppressed signaling pathways in this model
expression would occur later in tumor progression, as indeed will more closely resemble those occurring in human malignan-
appears to be the case (Bos, 1988). cies containing K-ras mutations. Moreover, the lessons learned
While this manuscript was in preparation, Guerra and col- here may also be applicable to studies of other oncogenes.
leagues reported that an endogenous K-rasG12V-IRES-BGeo allele
could immortalize MEFs and stimulate the production of pulmo- Experimental procedures
nary hyperplasias and neoplasias (Guerra et al., 2003). Signifi-
Mouse strains and tumor modelscant differences exist between our findings and the report of
The LSL-K-rasG12D strain was interbred to Prmcre mice (O’Gorman et al.,Guerra and colleagues. First, we describe morphological alter-
1997) and CMV-cre mice (Schwenk et al., 1995) to evaluate the effects ofations, focus formation, and cooperation with E1a in K-rasG12D-
K-rasG12D expression during development. Also, LSL-K-rasG12D mice were
expressing MEFs, whereas these phenotypes were absent in infected with aerosolized adenoviral-cre to produce pulmonary epithelial
K-rasG12V-IRES-Bgeo-expressing MEFs. Second, the Lox-K-rasG12D hyperplasias (Jackson et al., 2001), and interbred to Fabp-cre mice (Saam
MEFs have enhanced proliferative properties with accompa- and Gordon, 1999), K14-cre and K14-creER mice (Vasioukhin et al., 1999),
and MMTV-cre mice (Wagner et al., 1997) to generate epithelial hyperplasiasnying Cdk2 and Cdk4 cyclin-dependent kinase complex activa-
in bitransgenic mice.tion, whereas these properties were not demonstrated by
Guerra and colleagues. Third, Lox-K-rasG12D MEFs demonstrate
MEFsthe attenuation of MAPK and PI3K activation following serum
Early passage MEFs (p3-4) were used at the initiation of all experiments.
stimulation, whereas K-rasG12V-IRES-BGeo MEFs demonstrate activa- LSL-K-rasG12D mice were successively crossed to p53/ mice to generate
tion of these signaling pathways in response to EGF. Finally, a LSL-K-rasG12D ;p53/ MEFs. Mice and MEFs were on a mixed 129 Sv/
C57BL/6 background. MEFs were grown in 10% FCS/DMEM/25 mM HEPESthematic message of Guerra and colleagues is that endogenous
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that identifies senescent human cells in culture and in aging skin in vivo.and serum starved overnight in the same media supplemented with
Proc. Natl. Acad. Sci. USA 92, 9363–9367.0.1% FCS.
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